Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh Le Maux, Amélie, Pignol, Bernadette, Behr-Roussel, Delphine, Blachon, Jean-Luc, Chabrier, Pierre-Etienne, Compagnie, Sandrine, Picaut, Philippe, Bernabé, Jacques, Giuliano, François, Denys, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690145/
https://www.ncbi.nlm.nih.gov/pubmed/26694464
http://dx.doi.org/10.3390/toxins7124896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690145/
https://www.ncbi.nlm.nih.gov/pubmed/26694464
http://dx.doi.org/10.3390/toxins7124896

Ejemplares similares